Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

MLA

Blay, Jean-Yves, et al. “Ombrabulin plus Cisplatin versus Placebo plus Cisplatin in Patients with Advanced Soft-Tissue Sarcomas after Failure of Anthracycline and Ifosfamide Chemotherapy: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet. Oncology, vol. 16, no. 5, May 2015, pp. 531–40. EBSCOhost, https://doi.org/10.1016/S1470-2045(15)70102-6.

APA

Blay, J.-Y., Pápai, Z., Tolcher, A. W., Italiano, A., Cupissol, D., López-Pousa, A., Chawla, S. P., Bompas, E., Babovic, N., Penel, N., Isambert, N., Staddon, A. P., Saâda-Bouzid, E., Santoro, A., Franke, F. A., Cohen, P., Le-Guennec, S., & Demetri, G. D. (2015). Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 16(5), 531–540. https://doi.org/10.1016/S1470-2045(15)70102-6

Chicago

Blay, Jean-Yves, Zsuzsanna Pápai, Anthony W Tolcher, Antoine Italiano, Didier Cupissol, Antonio López-Pousa, Sant P Chawla, et al. 2015. “Ombrabulin plus Cisplatin versus Placebo plus Cisplatin in Patients with Advanced Soft-Tissue Sarcomas after Failure of Anthracycline and Ifosfamide Chemotherapy: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet. Oncology 16 (5): 531–40. doi:10.1016/S1470-2045(15)70102-6.